Moneycontrol
Get App
you are here: HomeNewsBusiness
Last Updated : Mar 22, 2019 12:11 PM IST | Source: PTI

Alembic Pharma gets USFDA nod for conjunctivitis treatment drug

The approved product is therapeutically equivalent to the reference listed drug Optivar Ophthalmic Solution of Mylan Specialty L P.

Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Alembic Pharmaceuticals on Friday said it has received approval from the US health regulator for Azelastine Hydrochloride Ophthalmic Solution used for treatment of allergic conjunctivitis.

The approved product is therapeutically equivalent to the reference listed drug Optivar Ophthalmic Solution of Mylan Specialty L P.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Azelastine Hydrochloride Ophthalmic Solution, 0.05 per cent, Alembic Pharmaceuticals said in a BSE filing.

Close

Quoting IQVIA data, Alembic Pharmaceuticals said Azelastine Hydrochloride Ophthalmic Solution, 0.05 per cent, has an estimated market size of USD 8.5 million for twelve months ending December 2018.

The company currently has a total of 89 ANDA approvals (76 final approvals and 13 tentative approvals) from the USFDA, it added.

Shares of Alembic Pharmaceuticals were trading 0.55 per cent lower at Rs 537 apiece on the BSE.

Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.

First Published on Mar 22, 2019 11:54 am
Sections
Follow us on